Annual Accounts Payable:
$21.61M+$17.66M(+446.75%)Summary
- As of today, RXRX annual accounts payable is $21.61 million, with the most recent change of +$17.66 million (+446.75%) on December 31, 2024.
- During the last 3 years, RXRX annual accounts payable has risen by +$18.79 million (+666.69%).
- RXRX annual accounts payable is now at all-time high.
Performance
RXRX Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly Accounts Payable:
$13.94M-$5.38M(-27.85%)Summary
- As of today, RXRX quarterly accounts payable is $13.94 million, with the most recent change of -$5.38 million (-27.85%) on September 30, 2025.
- Over the past year, RXRX quarterly accounts payable has increased by +$11.68 million (+516.59%).
- RXRX quarterly accounts payable is now -44.45% below its all-time high of $25.09 million, reached on March 31, 2025.
Performance
RXRX Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
RXRX Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1Y1 Year | +446.8% | +516.6% |
| 3Y3 Years | +666.7% | +258.2% |
| 5Y5 Years | +1614.0% | - |
RXRX Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | |
|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +666.7% | -44.5% | +568.0% |
| 5Y | 5-Year | at high | +1912.4% | -44.5% | +1197.5% |
| All-Time | All-Time | at high | +1912.4% | -44.5% | +1197.5% |
RXRX Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2025 | - | $13.94M(-27.9%) |
| Jun 2025 | - | $19.31M(-23.0%) |
| Mar 2025 | - | $25.09M(+16.1%) |
| Dec 2024 | $21.61M(+446.7%) | $21.61M(+856.3%) |
| Sep 2024 | - | $2.26M(-39.9%) |
| Jun 2024 | - | $3.76M(-26.5%) |
| Mar 2024 | - | $5.12M(+29.4%) |
| Dec 2023 | $3.95M(-13.8%) | $3.95M(-7.3%) |
| Sep 2023 | - | $4.26M(+104.5%) |
| Jun 2023 | - | $2.09M(-50.9%) |
| Mar 2023 | - | $4.25M(-7.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2022 | $4.59M(+62.7%) | $4.59M(+17.9%) |
| Sep 2022 | - | $3.89M(+22.5%) |
| Jun 2022 | - | $3.18M(-23.7%) |
| Mar 2022 | - | $4.16M(+47.6%) |
| Dec 2021 | $2.82M(+162.5%) | $2.82M(-55.4%) |
| Sep 2021 | - | $6.33M(+97.9%) |
| Jun 2021 | - | $3.20M(+2.3%) |
| Mar 2021 | - | $3.13M(+191.0%) |
| Dec 2020 | $1.07M(-14.8%) | - |
| Dec 2020 | - | $1.07M |
| Dec 2019 | $1.26M | - |
FAQ
- What is Recursion Pharmaceuticals, Inc. annual accounts payable?
- What is the all-time high annual accounts payable for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. annual accounts payable year-on-year change?
- What is Recursion Pharmaceuticals, Inc. quarterly accounts payable?
- What is the all-time high quarterly accounts payable for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. quarterly accounts payable year-on-year change?
What is Recursion Pharmaceuticals, Inc. annual accounts payable?
The current annual accounts payable of RXRX is $21.61M
What is the all-time high annual accounts payable for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high annual accounts payable is $21.61M
What is Recursion Pharmaceuticals, Inc. annual accounts payable year-on-year change?
Over the past year, RXRX annual accounts payable has changed by +$17.66M (+446.75%)
What is Recursion Pharmaceuticals, Inc. quarterly accounts payable?
The current quarterly accounts payable of RXRX is $13.94M
What is the all-time high quarterly accounts payable for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high quarterly accounts payable is $25.09M
What is Recursion Pharmaceuticals, Inc. quarterly accounts payable year-on-year change?
Over the past year, RXRX quarterly accounts payable has changed by +$11.68M (+516.59%)